StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

C21 · Pharmaceuticals · Global

Phase 3 oncology bispecific antibody trials

Global: 160 in as of 27 Sep 2026.

  • 160 Latest · Global · as of 27 Sep 2026
  • Irregular Release cadence
  • 1 Record · 1 region · 2026

Verified 27 Sep 2026 · 1 publisher

CSV JSON Cite and reuse

The figure

One published observation so far. A chart follows as soon as a second period is published.

Fig 1 · C21 · 1 regionIrregular

Phase 3 oncology bispecific antibody trials

Global, as of 27 Sep 2026

1 observation
160 Global · as of 27 Sep 2026 · ClinicalTrials.gov · full record
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org

Every record

1 record · 1 region · 2026. Each period links to its record: the value, the quote it was read from, and the document.

Phase 3 oncology bispecific antibody trials: every record, grouped by region, newest first.
Period Value Source Type
Global 1 record
as of 27 Sep 2026 160 ClinicalTrials.gov · 27 Sep 2026

Download this data

CSV data JSON series API

Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.

Use and publication rights

  • View, cite and link: free

    Quote any number, cite this page or a single record, and link to it anywhere.

  • Copy, chart and republish: free with attribution

    The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.

  • The source documents: the publisher's terms

    Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.

How this measure is built

Definition
Count of interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 or Phase 2/3, any start date.
Measure
One slice of Clinical trial registrations ( basis: clinicaltrials gov registry, counting rule: phase 3, form: count, segment: bsab ) . Total number of clinical trials registered with a clinical trials registry platform. Region and period are columns on every record, not slices.
Limitations
Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
Verification
Each value, unit, period and place was checked against its quote before publication. See the methodology and the corrections process.

Sources · 1 document

Document Publisher Published Data points
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 ClinicalTrials.gov — 1

Other slices of clinical trial registrations

Frequently asked questions

What is the latest phase 3 oncology bispecific antibody trials?

Global: 160 in as of 27 Sep 2026.

Where does this data come from?

From 1 document published by ClinicalTrials.gov. Every figure on this page links to its record, which quotes the sentence or table row the number was read from.

How often is it updated?

Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.

Can I use this data?

Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.

Cite this page

Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). Phase 3 oncology bispecific antibody trials [Data set]. Retrieved September 29, 2026, from https://statorigin.org/indicators/ctgov-bsab-phase-3-trials

"Phase 3 oncology bispecific antibody trials." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-bsab-phase-3-trials. Accessed 29 Sep. 2026.

StatOrigin. "Phase 3 oncology bispecific antibody trials." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/indicators/ctgov-bsab-phase-3-trials.

@misc{statorigin_ctgov_bsab_phase_3_trials_2026, title = {Phase 3 oncology bispecific antibody trials}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-bsab-phase-3-trials}, note = {Data set. Accessed 2026-09-29} }